X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - ZACKS.COM - All Stories - 27/Jun 14:26

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.

Articles similaires

Sorry! Image not available at this time

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

drugs.com - 26/Jun 19:06

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

Sorry! Image not available at this time

Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus

pharmabiz.com - 04/Jul 00:00

Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...

Sorry! Image not available at this time

Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

drugs.com - 05/Jul 00:07

Basel, 04 July 2024 - Roche announced today that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq (atezolizumab) and...

Sorry! Image not available at this time

Pulnovo Medical begins patient enrollment in Portugal for global study of PADN technology in treating pulmonary hypertension associated with left heart disease

pharmabiz.com - 03/Jul 00:00

Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of pulmonary hypertension (PH) and heart failure (HF), announced the...

Sorry! Image not available at this time

First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

drugs.com - 03/Jul 04:07

GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell...

Sorry! Image not available at this time

Genentech Provides Update on Phase II/III Skyscraper-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer

drugs.com - 03/Jul 06:07

South San Francisco, CA -- July 3, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III...

Sorry! Image not available at this time

Utilizing Lisinopril for Hypertension Management

acedessays.com - 30/Jun 22:17

  The presentation must include information about the: Drug pharmacology, pharmacokinetics Brand name Generic name Dosing Indications for use Side...

Sorry! Image not available at this time

Imugene delivers first combo dose in bile tract cancer study

thewest.com.au - 24/Jun 08:20

Imugene has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the initial phase of a...

Sorry! Image not available at this time

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

healthtechzone.com - 25/Jun 11:00

Sorry! Image not available at this time

AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use

zacks.com - 02/Jul 15:00

The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data...

Les derniers communiqués